Cefalexin 500 mg BID for 7 Days is Effective for Non-Purulent Cellulitis
Yes, cefalexin (cephalexin) 500 mg twice daily for 7 days is an appropriate and FDA-approved treatment for non-purulent cellulitis, particularly for skin and skin structure infections caused by susceptible streptococci and staphylococci. 1
FDA-Approved Dosing
The FDA label explicitly states that 500 mg every 12 hours may be administered for skin and skin structure infections 1. This twice-daily dosing regimen is specifically approved for these indications and provides adequate coverage for the typical pathogens involved in non-purulent cellulitis.
Clinical Evidence Supporting BID Dosing
Multiple clinical studies demonstrate that twice-daily cephalexin is equally effective as four-times-daily dosing:
- A randomized study of 154 patients with skin infections showed >97% efficacy with both BID and QID regimens, with no significant difference in outcomes 2
- A multi-center study of 752 patients with soft tissue infections demonstrated >80% cure rates with twice-daily dosing 3
- A comparative study showed 96.5% satisfactory response with 500 mg BID versus 94% with QID dosing 4
The twice-daily regimen offers the advantage of improved patient adherence while maintaining equivalent clinical efficacy.
Important Caveats for Non-Purulent Cellulitis
Pathogen Identification Challenge
The 2014 IDSA guidelines highlight a critical limitation: in non-purulent cellulitis, the clinical isolation rate of a pathogen is <20%, leaving clinicians with an unconfirmed diagnosis 80% of the time 5. This means you're treating empirically based on the most likely pathogens (β-hemolytic streptococci, particularly Group A Streptococcus).
Coverage Considerations
Cephalexin provides excellent coverage for:
- Streptococcus pyogenes (Group A Strep)
- Penicillin-susceptible Staphylococcus aureus
- Other streptococcal species
However, cephalexin is NOT active against MRSA 1. If you suspect purulent infection, MRSA involvement, or if the patient fails to improve within 48-72 hours, you must consider alternative coverage.
Duration of Therapy
While the FDA label doesn't specify exact duration for cellulitis, 7 days is a reasonable treatment course for uncomplicated non-purulent cellulitis. The IDSA guidelines note that definitive duration of therapy remains an area needing further research 5.
For streptococcal infections specifically, the FDA recommends at least 10 days of treatment 1, so consider extending to 10 days if you have confirmed or strongly suspect streptococcal etiology.
When This Regimen May Not Be Sufficient
- Severe infections requiring hospitalization - consider IV antibiotics
- Suspected MRSA - add trimethoprim-sulfamethoxazole or use alternative agents
- Immunocompromised patients - may need broader coverage
- Failure to improve within 48-72 hours - reassess and consider alternative pathogens
- Recurrent cellulitis - investigate underlying risk factors (lymphedema, venous insufficiency) 5
Practical Monitoring
Patients should show clinical improvement (reduced erythema, warmth, swelling, pain) within 48-72 hours. Mark the borders of erythema at initial presentation to objectively assess progression or improvement. If worsening or no improvement occurs, consider treatment failure and need for alternative therapy.